NCT05585996View on ClinicalTrials.gov

Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

November 1, 2025

Study Completion Date

December 30, 2025

Conditions
Relapsed and Refractory B-cell Lymphoma
Interventions
BIOLOGICAL

CD19 CAR-T and CD19 CAR-DC

Intravenously injected CAR DC cells and followed by CAR T cells 4 hours later

Trial Locations (1)

310009

RECRUITING

2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hanzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER